A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicidesVAN HERREWEGE, Yven; VANHAM, Guido; MICHIELS, Jo et al.Antimicrobial agents and chemotherapy. 2004, Vol 48, Num 10, pp 3684-3689, issn 0066-4804, 6 p.Article

Nonnucleoside Reverse Transcriptase Inhibitor Concentrations During Treatment Interruptions and the Emergence of Resistance: A Substudy of the ISS-PART TrialPIRILLO, Maria; PALMISANO, Lucia; VELLA, Stefano et al.AIDS research and human retroviruses. 2010, Vol 26, Num 5, pp 541-545, issn 0889-2229, 5 p.Article

Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiationMANGIACASALE, Rosamaria; PITTOGGI, Carmine; LAVIA, Patrizia et al.Oncogene (Basingstoke). 2003, Vol 22, Num 18, pp 2750-2761, issn 0950-9232, 12 p.Article

Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patientsALLAVENA, Clotilde; FERRE, Virginie; LAUNAY, Odile et al.Journal of acquired immune deficiency syndromes (1999). 2005, Vol 39, Num 3, pp 300-306, issn 1525-4135, 7 p.Article

Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitorFERRIS, Robert G; HAZEN, Richard J; SHORT, Steven A et al.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 10, pp 4046-4051, issn 0066-4804, 6 p.Article

Modulation of human BCRP (ABCG2) activity by anti-HIV drugsWEISS, Johanna; ROSE, Johanna; HENRIKE STORCH, Caroline et al.Journal of antimicrobial chemotherapy (Print). 2007, Vol 59, Num 2, pp 238-245, issn 0305-7453, 8 p.Article

No pol Mutation is Associated Independently with the Lack of Immune Recovery in Patients Infected with HIV and Failing Antiretroviral TherapyGIANOTTI, Nicola; GALLI, Laura; DI GIAMBENEDETTO, Simona et al.Journal of medical virology. 2011, Vol 83, Num 3, pp 391-398, issn 0146-6615, 8 p.Article

Prevention of HIV-1 infection by platinum triazinesVZOROV, A. N; BHATTACHARYYA, D; MARZILLI, L. G et al.Antiviral research. 2005, Vol 65, Num 2, pp 57-67, issn 0166-3542, 11 p.Article

Efficacy, Safety, and Tolerability of Etravirine With and Without Darunavir/Ritonavir or Raltegravir in Treatment-Experienced Patients: Analysis of the Etravirine Early Access Program in the United StatesTOWNER, William; LALEZARI, Jacob; HOOGSTOEL, Annemie et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 53, Num 5, pp 614-618, issn 1525-4135, 5 p.Article

The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors : Implications for once-daily dosingBACK, David J; BURGER, David M; FLEXNER, Charles W et al.Journal of acquired immune deficiency syndromes (1999). 2005, Vol 39, pp S1-S23, issn 1525-4135, SUP1Article

Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patientsFÄTKENHEUER, Gerd; STASZEWSKI, Schlomo; PLETTENBURG, Andreas et al.AIDS (London). 2009, Vol 23, Num 16, pp 2117-2124, issn 0269-9370, 8 p.Article

Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infectionHAUBRICH, Richard H; RIDDLER, Sharon A; RIBAUDO, Heather et al.AIDS (London). 2011, Vol 25, Num 18, pp 2269-2278, issn 0269-9370, 10 p.Article

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimenFOX, Zoe; PHILLIPS, Andrew; COHERE, Cal et al.AIDS (London). 2008, Vol 22, Num 17, pp 2279-2289, issn 0269-9370, 11 p.Article

Antiviral Activity of MK-4965, a Novel Nonnucleoside Reverse Transcriptase InhibitorLAI, Ming-Tain; MUNSHI, Vandna; TOUCH, Sinoeun et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 6, pp 2424-2431, issn 0066-4804, 8 p.Article

Reverse Transcriptase Inhibitors as Potential Colorectal MicrobicidesHERRERA, Carolina; CRANAGE, Martin; MCGOWAN, Ian et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 5, pp 1797-1807, issn 0066-4804, 11 p.Article

How common is the non-nucleoside reverse transcriptase inhibitor mutation E138K in clinical practice?BRADSHAW, Daniel; MANDALIA, Sundhiya; NELSON, Mark et al.The Journal of infection. 2011, Vol 63, Num 2, pp 172-173, issn 0163-4453, 2 p.Article

Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance : evidence of transmitted resistance in rural South AfricaBARTH, Roos E; WENSING, Annemarie M; TEMPELMAN, Hugo A et al.AIDS (London). 2008, Vol 22, Num 16, pp 2210-2212, issn 0269-9370, 3 p.Article

Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytesRODRIGUEZ DE LA CONCEPCION, M. Luisa; YUBERO, Pilar; DOMINGO, Joan C et al.Antiviral therapy (London). 2005, Vol 10, Num 4, pp 515-526, issn 1359-6535, 12 p.Article

In combination, nucleoside reverse transcriptase inhibitors have significant effects on 3T3-L1 adipocyte lipid accumulation and survivalKOSMISKI, Lisa A; MILLER, Heidi L; KLEMM, Dwight J et al.Antiviral therapy (London). 2006, Vol 11, Num 2, pp 187-195, issn 1359-6535, 9 p.Article

SAMHD1 Specifically Affects the Antiviral Potency of Thymidine Analog HIV Reverse Transcriptase InhibitorsBALLANA, Ester; BADIA, Roger; TERRADAS, Gerard et al.Antimicrobial agents and chemotherapy. 2014, Vol 58, Num 8, pp 4804-4813, issn 0066-4804, 10 p.Article

Topical Nonnucleoside Reverse Transcriptase Inhibitor MC 1220 Partially Prevents Vaginal RT-SHIV Infection of MacaquesSTOLTE-LEEB, Nicole; LODDO, Roberta; STAHL-HENNIG, Christiane et al.AIDS research and human retroviruses. 2011, Vol 27, Num 9, pp 933-943, issn 0889-2229, 11 p.Article

Long term adverse effects related to nucleoside reverse transcriptase inhibitors: Clinical impact of mitochondrial toxicityMAAGAARD, Anne; KVALE, Dag.Scandinavian journal of infectious diseases. 2009, Vol 41, Num 11-12, pp 808-817, issn 0036-5548, 10 p.Article

New antiretroviral drugsGULICK, R. M.Clinical microbiology and infection. 2003, Vol 9, Num 3, pp 186-193, issn 1198-743X, 8 p.Article

Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageableSEDEN, Kay; BACK, David; KHOO, Saye et al.Journal of antimicrobial chemotherapy (Print). 2009, Vol 64, Num 1, pp 5-8, issn 0305-7453, 4 p.Article

Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitnessBANGSBERG, David R; ACOSTA, Edward P; GUPTA, Reena et al.AIDS (London). 2006, Vol 20, Num 2, pp 223-231, issn 0269-9370, 9 p.Article